Authors :
Ambati Hima Bindu; Nomula Akhila Reddy; Policepatel Vamshikrishna; Srishti Deshpande; Shaikh Mohmed Adnan Mohmed Javid
Volume/Issue :
Volume 9 - 2024, Issue 4 - April
Google Scholar :
https://tinyurl.com/4h8kjntk
Scribd :
https://tinyurl.com/yc3tknu9
DOI :
https://doi.org/10.38124/ijisrt/IJISRT24APR1750
Abstract :
Type 2 diabetes, a chronic, progressive
condition, causes hyperglycemia in the heart, liver,
skeletal muscle, and adipose tissue. The latest forecasts
show 592 million diabetics globally by 2035, up from 382
million in 2013. A new line of medicines blocks the
kidney-based transporter protein sodium glucose co-
transporter-2 (SGLT2) independently of insulin,
complementing insulin treatment. Dapagliflozin
(Forxiga) is a new EU-approved type 2 diabetes
medication. This insulin-dependent process boosts urine
glucose excretion. By specifically and potentially
inhibiting SGLT2, dapagliflozin decreases blood glucose
without insulin. Dapagliflozin had no clinically
meaningful pharmacokinetic interactions with
metformin, pioglitazone, sitagliptin, or glimepiride in
healthy volunteers. The principal findings of clinical
trials employing dapagliflozin to treat type 2 diabetes
showed that the prescribed dosage (10 mg/day) was
beneficial. Dapagliflozin works best with type 2 diabetes
and cardiovascular disease or risk factors.
Keywords :
Dapagliflozin, Type 2 Diabetes, SGLT-2 Inhibitor.
Type 2 diabetes, a chronic, progressive
condition, causes hyperglycemia in the heart, liver,
skeletal muscle, and adipose tissue. The latest forecasts
show 592 million diabetics globally by 2035, up from 382
million in 2013. A new line of medicines blocks the
kidney-based transporter protein sodium glucose co-
transporter-2 (SGLT2) independently of insulin,
complementing insulin treatment. Dapagliflozin
(Forxiga) is a new EU-approved type 2 diabetes
medication. This insulin-dependent process boosts urine
glucose excretion. By specifically and potentially
inhibiting SGLT2, dapagliflozin decreases blood glucose
without insulin. Dapagliflozin had no clinically
meaningful pharmacokinetic interactions with
metformin, pioglitazone, sitagliptin, or glimepiride in
healthy volunteers. The principal findings of clinical
trials employing dapagliflozin to treat type 2 diabetes
showed that the prescribed dosage (10 mg/day) was
beneficial. Dapagliflozin works best with type 2 diabetes
and cardiovascular disease or risk factors.
Keywords :
Dapagliflozin, Type 2 Diabetes, SGLT-2 Inhibitor.
